Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
INKT MiNK Therapeutics
2.220+0.070+3.26%
Close
02/03 16:00 ET
2.2200.0000.00%
Post Mkt Price 02/03 16:26 ET
High
2.270
Open
2.060
Turnover
18.02K
Low
2.060
Pre Close
2.150
Volume
8.15K
Post-Market
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
MiNK Therapeutics to Participate in B. Riley Securities Oncology Conference
MiNK Therapeutics (NASDAQ:INKT) Stock Price Down 2.2%
MiNK Therapeutics, Inc. (NASDAQ:INKT – Get Rating) shares dropped 2.2% during trading on Tuesday . The stock traded as low as $2.27 and last traded at $2.27. Approximately 11,370 shares traded hands
Analyzing MiNK Therapeutics (NASDAQ:INKT) and Anavex Life Sciences (NASDAQ:AVXL)
MiNK Therapeutics (NASDAQ:INKT – Get Rating) and Anavex Life Sciences (NASDAQ:AVXL – Get Rating) are both small-cap medical companies, but which is the better business? We will contrast the two busin
MiNK Therapeutics (NASDAQ:INKT) Versus Voyager Therapeutics (NASDAQ:VYGR) Head to Head Comparison
Voyager Therapeutics (NASDAQ:VYGR – Get Rating) and MiNK Therapeutics (NASDAQ:INKT – Get Rating) are both small-cap medical companies, but which is the better stock? We will compare the two companies
MiNK Therapeutics (NASDAQ:INKT) Stock Price Down 0.4%
MiNK Therapeutics, Inc. (NASDAQ:INKT – Get Rating) shares traded down 0.4% during mid-day trading on Wednesday . The stock traded as low as $2.50 and last traded at $2.51. 7,858 shares changed hands
MiNK Therapeutics (NASDAQ:INKT) Shares Down 0.4%
MiNK Therapeutics, Inc. (NASDAQ:INKT – Get Rating)'s stock price dropped 0.4% during trading on Wednesday . The stock traded as low as $2.50 and last traded at $2.51. Approximately 7,858 shares trade
MiNK Therapeutics to Participate in Evercore ISI HealthCONx Conference
NEW YORK, Nov. 17, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-sh
MiNK Therapeutics, Inc. Forecasted to Post Q1 2023 Earnings of ($0.26) Per Share (NASDAQ:INKT)
MiNK Therapeutics, Inc. (NASDAQ:INKT – Get Rating) – Research analysts at B. Riley issued their Q1 2023 earnings estimates for MiNK Therapeutics in a note issued to investors on Monday, November 1
B. Riley Comments on MiNK Therapeutics, Inc.'s Q2 2023 Earnings (NASDAQ:INKT)
MiNK Therapeutics, Inc. (NASDAQ:INKT – Get Rating) – Investment analysts at B. Riley issued their Q2 2023 earnings per share (EPS) estimates for shares of MiNK Therapeutics in a note issued to inve
Why Tattooed Chef Shares Dipped Around 15%; Here Are 95 Biggest Movers From Friday
Gainers ShiftPixy, Inc. (NASDAQ:PIXY) shares surged 56.6% to settle at $19.10 on Friday.Shares of several companies in the broader industrial space traded higher on continued hopes of softer Fed poli
Company Overview
More
MiNK Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of allogeneic invariant natural killer T cell therapies to treat cancer and other immune mediated diseases. The company was founded in 2017 and is headquartered in New York, NY.
CEO： Dr. Jennifer S. Buell, PhD
Market： NASDAQ
Listing Date： 10/15/2021
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet